Hypera S.A. (HYPMY)
OTC
Closed
Sep 25, 2026
Day's Range
4.6352 wk Range
3.71Overview - HYPMY - Hypera S.A.
Key Statistics
Valuation
Enterprise Value
1.98B
P/E (Trailing)
‪10.84‬
PEG Ratio
‪2.03‬
Price / Sales (TTM)
‪0.43‬
Price / Book
‪1.32‬
EV / EBITDA
‪3.63‬
Profitability
Gross Margin
‪61.78%‬
Profit Margin
‪19.82%‬
Operating Margin
‪28.66%‬
Return on Assets
‪6.30%‬
Return on Equity
‪13.16%‬
Ownership
Shares Outstanding
703.99M
Float
305.72M
Held by Insiders
‪0.00%‬
Held by Institutions
‪0.01%‬
Price stats
Beta
‪0.07‬
50-Day Avg
‪4.41‬
200-Day Avg
‪4.38‬
Dividends
Payout Ratio
‪41.99%‬
Frequency
Quarterly
Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - HYPMY - Hypera S.A.
Peers - HYPMY - Hypera S.A.
Peer Comparison
Compared with companies in Drug Manufacturers - Specialty & Generic listed on OTC.
- HYPMYOTCHypera S.A.3.75BMarket Cap+29.77%52-week change10.84P/E (Trailing)‪19.82%‬Profit Margin
- MKGAFOTCMerck KGaA67.92BMarket Cap+9.27%52-week change25.32P/E (Trailing)‪11.21%‬Profit Margin
- MKKGYOTCMerck KGaA Sponsored ADR67.10BMarket Cap+8.97%52-week change24.90P/E (Trailing)‪11.21%‬Profit Margin
- GALDYOTCGalderma Group AG Unsponsored ADR45.20BMarket Cap+7.87%52-week change53.10P/E (Trailing)‪14.57%‬Profit Margin
- GDERFOTCGalderma Group AG44.15BMarket Cap+11.81%52-week change51.88P/E (Trailing)‪14.57%‬Profit Margin
- JHPCYOTCJiangsu Hengrui Pharmaceuticals Co. Ltd.43.14BMarket Cap-30.46%52-week change37.14P/E (Trailing)‪86.20%‬Profit Margin
- HLNCFOTCHaleon plc38.69BMarket Cap+1.79%52-week change18.58P/E (Trailing)‪14.55%‬Profit Margin
Profile Summary - HYPMY - Hypera S.A.
About
Hypera S.A. is a leading Brazilian pharmaceutical company engaged in the research, development, manufacturing, and marketing of a diverse range of health-related products. Primarily, it focuses on the production of over-the-counter medications, prescription drugs, and consumer health products, serving a broad spectrum…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
